Biomerica (BMRA) Return on Capital Employed (2011 - 2026)
Biomerica (BMRA) reported Return on Capital Employed of 137.43% for Q1 2026, down 4760.0% on a YoY basis from 2.95% in Q1 2025, and down 26.47% sequentially from 108.67% in Q4 2025.
Biomerica (BMRA) Return on Capital Employed (2011 - 2026) Analysis & Trends
Biomerica (BMRA) has 16 years of Return on Capital Employed data on file, last reported at 137.43% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed fell 4760.0% year-over-year to 137.43%; the trailing twelve-month figure through Feb 2026 stood at 137.43% (down 4760.0% YoY), and the FY2025 full-year result was 87.67%, down 2169.0% from the prior year.
- Return on Capital Employed slipped to 137.43% in Q1 2026, from 108.67% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 36.4% in Q2 2022 to a low of 137.43% in Q1 2026.
- A 5-year average of 81.76% and a median of 83.86% in 2024 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed jumped 3007 bps in 2022 and plunged 4864 bps in 2024, its largest moves.
- Tracing BMRA's Return on Capital Employed over 5 years: stood at 64.25% in 2022, then gained by 8 bps to 59.11% in 2023, then sank by 75 bps to 103.39% in 2024, then fell by 5 bps to 108.67% in 2025, then decreased by 26 bps to 137.43% in 2026.
- Business Quant data shows BMRA's Return on Capital Employed at 137.43% in Q1 2026, 108.67% in Q4 2025, and 103.79% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 9.61% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 12.24% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 8.02% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 9.62% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 11.13% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 24.24% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 8.38% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 9.30% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Biomerica | 4.85 Mn | 3.51 Mn | -44,000.00 | -137.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | -137.43% |
| Nov 30, 2025 | -108.67% |
| Aug 31, 2025 | -103.79% |
| May 31, 2025 | -104.36% |
| Feb 28, 2025 | -89.83% |
| Nov 30, 2024 | -103.39% |
| Aug 31, 2024 | -101.45% |
| May 31, 2024 | -83.86% |
| Feb 29, 2024 | -73.40% |
| Nov 30, 2023 | -59.11% |
| Aug 31, 2023 | -52.81% |
| May 31, 2023 | -76.95% |
| Feb 28, 2023 | -93.21% |
| Nov 30, 2022 | -64.25% |
| Aug 31, 2022 | -53.56% |
| May 31, 2022 | -36.40% |
| Feb 28, 2022 | -47.43% |
| Nov 30, 2021 | -77.87% |
| Aug 31, 2021 | -70.11% |
| May 31, 2021 | -66.47% |